Hosted on MSN1mon
Simcere’s Sanbexin Tablets Approved for Stroke Treatment in China
The innovative sublingual formulation, combining edaravone and dexborneol, offers a faster absorption method, enhancing stroke treatment flexibility. This advancement aligns with Simcere’s ...
The Victoria Advocate1mon
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin ® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets ...
Yahoo Finance23d
Simcere Pharmaceutical Group Limited (2096.HK)
On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been ...
Yahoo Finance9d
Simcere Pharmaceutical Group Ltd (S2P.DU)
On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved ...
Yahoo Finance1mon
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin ® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an ...